Current Partnering seeks out the best articles from various sources, to keep you updated on partnering best practice and broader topics currently being discussed and debated.
Dealmakers weekly review – February 6 2012 – Merck KgaA, Threshold, Bill and Melinda Gates Foundation, AstraZenenca, Actavis
February 7, 2012 : Big Pharma, M&A, partnering
The week was relatively quiet until the end of week announcement by Merck KGaA of a $550 million partnership with Threshold for the co-development and commercialization of TH-302 more »
VC spend in life sciences grew in 2011
February 6, 2012 : medical device, venture capital
Published by MassDevice.
Venture capital investors spent 21% more backing life science startups in 2011 than in 2010, according to PricewaterhouseCoopers; also, VCs in the Valley lose confidence; Greenway Medical prices IPO; does Abbott need a new CEO?; and analysts’ ups and downs. more »
Partnering 2011: Leading deals by upfront payment, another measure of deal value to the licensee
February 6, 2012 : Big Pharma, partnering, partnering agreements, partnering terms
Analysis of date from the leading deals and alliances service Current Agreements, shows that many deals have eye watering headline values, however these deals often require an enormous amount to be successful during the development phases in order for the full value of the deal to be realized more »
Dealmakers weekly review – January 30 2012 – Roche, Illumina, Amgen, Micromet, Celgene, Avila, Boehringer Ingelheim, Priaxon
January 31, 2012 : Big Pharma, dealtalk, financings, M&A
Three mega M&A announcements and a slowing of partnering activity more »
Top M&A 2011:over $130 billion bet on life sciences consolidation
January 30, 2012 : Big Pharma, M&A
Analysis of data from the leading deals and alliances servicer Current Agreements, shows that the top twenty M&A deals announced in the life sciences sector during 2011 had a combined value in excess of $130 billion more »
Top twenty partnering deals of 2011 have a combined value of over $21 billion
January 24, 2012 : Big Pharma, partnering, partnering agreements, partnering terms
Analysis of data from the leading deals and alliances service Current Agreements, shows that the top twenty partnering deals in the life sciences have a combined value of $21.5 billion more »
Dealmakers weekly review – January 23 2012 – Genentech, Paragon Bioservices, Neurocrine Biosciences
January 23, 2012 : Big Pharma, financings, Genentech, M&A, partnering
The start of 2012 has continued to see a surge in partnering announcements. This mirrors the level of dealmaking we saw just before the end of 2011 – where companies were wrapping up deals in time for the company year end more »
Biotech funding hits 4-year high as startups suffer
January 23, 2012 : dealtalk
Venture capital investment in biotechnology increased 22 percent last year, while the number of those receiving their first funding declined. more »
Biotech investors declare it’s never too early to plan an exit
January 17, 2012 : dealtalk, investment
It’s never too early to plan an exit strategy. Panelists at the Biotech Showcase™ 2012 luncheon plenary session Monday all agreed that, although that strategy may include an IPO, exit planning should include other strategies as well. more »
Lights are flashing green for biotech investment in China
January 17, 2012 : china
How can investors in the West take advantage of what is happening in the life science sector in China, and what are its implications for the future of US VC funding? A featured panel at Biotech Showcase™ 2012 sought some answers. more »
